RB55ZW48XG | 2376765-57-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: RB55ZW48XG
• 英文别名: (4aR,10bR)-8-chloro-1'-(2-imidazol-1-ylethyl)-5,5-dimethylspiro[2,4,4a,10b-tetrahydropyrano[3,2-c]chromene-3,4'-piperidine]
• CAS: 2376765-57-8
• 化学式: C₂₃H₃₀ClN₃O₂
• 分子量: 416.0
• InChiKey: QKAZUVQTHFXMLS-CTNGQTDRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  39.5
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• DIHYDROCHROMENE DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20200216461A1

  公开（公告）日：2020-07-09

  The present invention relates to the compound of formula (I) wherein R 1A , R 1B , R 1C , and R 1D are hydrogen atom, etc., R 2A and R 2B are hydrogen atom, etc., R 3A , R 3B , R 3C , and R 3D are hydrogen atom, etc., L is bond, etc., V is C 1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.

  本发明涉及公式（I）的化合物，其中R1A，R1B，R1C和R1D是氢原子等，R2A和R2B是氢原子等，R3A，R3B，R3C和R3D是氢原子等，L是键等，V是C1-6烷基，Q是可选取代咪唑或其药学上可接受的盐，作为一种新的抗肿瘤剂，针对被认为与恶性肿瘤的持续增殖、转移或复发以及抗肿瘤剂的耐药性密切相关的CSCs。
• Dihydrochromene derivatives
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US10807993B2

  公开（公告）日：2020-10-20

  The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.

  本发明涉及式(I)化合物，其中R1A、R1B、R1C和R1D为氢原子等，R2A和R2B为氢原子等，R3A、R3B、R3C和R3D为氢原子等，L为键等、V是C1-6亚烷基，Q是任选取代的咪唑或其药学上可接受的盐，作为一种新型抗肿瘤药，靶向CSCs，CSCs被认为与恶性肿瘤的持续增殖、癌症的转移或复发以及对抗肿瘤药的耐药性密切相关。
• DIHYDROCHROMENE DERIVATIVES
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20210002290A1

  公开（公告）日：2021-01-07

  The present invention relates to the compound of formula (I) wherein R 1A , R 1B , R 1C , and R 1D are hydrogen atom, etc., R 2A and R 2B are hydrogen atom, etc., R 3A , R 3B , R 3C , and R 3D are hydrogen atom, etc., L is bond, etc., V is C 1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.